Posters

One-year follow-up of accelerated transepithelial corneal collagen cross-linking for progressive keratoconus with different corneal thickness

Poster Details

First Author: W.Jian CHINA

Co Author(s):    M. Tian   X. Zhang   Y. Shen   J. Shang   X. Zhou        

Abstract Details

Purpose:

To assess the safety and efficacy of accelerated transepithelial corneal collagen cross-linking (ATE-CXL) for progressive keratoconus in patients with varying corneal thickness.

Setting:

Single-center clinical institution

Methods:

One hundred and ten eyes of 97 patients with a mean age of 24.21 ± 5.36 years. This cohort was divided into four groups according to corneal thickness: A (>500 μm), B (451-500 μm), C (401-450 μm), and D (≤400 μm).All patients underwent ATE-CXL. Pre- and postoperatively at 1 month, 3 months, 6 months and 1 year, we documented maximum keratometry values(Kmax), ΔKmax, central corneal thickness (CCT), minimum corneal thickness (TCT), posterior central elevation (PCE), and posterior mean elevation (PME).We used repeated-measures analysis of variance to assess the outcomes of ATE-CXL in keratoconus patients at the above time intervals.

Results:

In groups A (15 eyes), B (39 eyes), C (31 eyes) and D (25 eyes), there were no significant differences between pre- and post-operative values of CCT, TCT, Kmax, PCE and PME. For Kmax, 1 of 15 eyes (6.7%) in group A, 12/39 eyes (30.8%) in group B, 9/31 eyes (29.0%) in group C, and 11/25 eyes in group D showed a decrease of ≥1 D.

Conclusions:

ATE-CXL is a safe and effective treatment for progressive keratoconus patients with different corneal thicknesses. The long-term effects of this procedure require further investigation.

Financial Disclosure:

None